We have shown for the first time that in T2DM, the steroidogenic effects of the allosteric LH/hCG-R-agonist TP3 are more stable as compared to hCG, including with prolonged administration, and this makes the use of allosteric LH/hCG-R-agonists very promising for mild, long-term correction of androgen deficiency in T2DM. This evidence concerns the gene PLOD1 and type 2 diabetes mellitus.